BMS 649

BMS 649 is a synthetic retinoid and retinoid X receptor (RXR) agonist. It binds to RXRalpha homodimers and selectively induces transactivation in CV-1 cells expressing RXRalpha over CV-1 cells expressing retinoic acid receptor alpha (RARalpha), RARbeta, or RARalpha and RXRalpha when used at a concentration of 0.1 µM. BMS 649 (1 µM), in combination with the RARalpha agonist BMS 753, induces morphological differentiation of F9 embryonal carcinoma cells. It prevents differentiation induced by phorbol-12-myristate-13-acetate (PMA, Cay-10008014) of THP-1 monocytes into macrophages. BMS 649 (25 mg/kg) reduces body weight and bone lengths when administered to newborn rats. It induces malformations in Xenopus embryos.Formal Name: 4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl]-benzoic acid. CAS Number: 146670-40-8. Synonyms: BMS 188649, SR 11237, UVI 2108. Molecular Formula: C24H28O4. Formula Weight: 380.5. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: Sparingly soluble: 1-10 mg/ml. SMILES: CC1(C)CCC(C)(C)C2=CC=C(C3(C4=CC=C(C(O)=O)C=C4)OCCO3)C=C21. InChi Code: InChI=1S/C24H28O4/c1-22(2)11-12-23(3,4)20-15-18(9-10-19(20)22)24(27-13-14-28-24)17-7-5-16(6-8-17)21(25)26/h5-10,15H,11-14H2,1-4H3,(H,25,26). InChi Key: ZZUKALQMHNSWTK-UHFFFAOYSA-N.